Make Informed Health Decisions
Talk to Docus AI Doctor, generate health reports, get them validated by Top Doctors from the US and Europe.
Author
Lilit BudoyanMedical necessity denials are becoming harder for labs to ignore, and AI is increasingly being used to catch the risk earlier.
Denial rates have been rising across healthcare, with more providers reporting denial rates above 10% each year, from 30% in 2022 to 38% in 2024 and 41% in 2025.
A provider orders an HbA1c, lipid panel, and comprehensive metabolic panel with a broad wellness diagnosis code.
The lab runs the tests. The report is generated. The claim goes out.
Weeks later, some lines are denied for medical necessity.
By then, the work is already done. The sample has been processed. Reagents have been used. Staff time has been spent. The lab cannot undo that work. It can only decide whether the denied claim is worth reworking.
For labs, the problem often starts before a claim is ever submitted. The diagnosis code may not support the test. The order may lack clinical documentation. The payer may see the test as too soon after a previous one.
By the time the denial arrives, the lab is already dealing with unpaid work.
The better approach is to prevent the problem earlier. AI can help labs catch medical necessity, documentation, and frequency risks at the order or requisition stage, before they become denied claims or audit concerns.

Most denial-prevention advice is written for hospitals, health systems, or physician practices. Labs work under a different reality.
Hospitals often control both the clinical documentation and the billing process. Labs usually do not.
Many labs receive orders from outside providers, which means they depend on information created outside their own workflow. If that information is vague, incomplete, or missing, the lab may not catch the problem until the claim is denied.
The risk often starts with small order-level issues:
This creates a gap that manual review cannot always close. The ordering provider moves on, while the lab is left with the cost of rework, appeals, or write-offs.
The same problem can look different across lab workflows. Some labs struggle with outside provider orders. Others face documentation gaps, frequency issues, or inconsistent order entry. In patient-facing workflows, the risk may come from incomplete patient information or unclear testing reasons.
The setting changes, but the core issue stays the same: poor order quality increases billing risk.
XiFin’s 2024 Payor Denial Impact Report, based on more than 20 million lab claims, shows that hospital outreach and clinical labs continue to face significant denial pressure. XiFin also reported that some Medicare Advantage plans paid clean claims at rates as low as 85%, compared with 98% for traditional fee-for-service Medicare.
Even when billing details are complete, a claim can still fail if the diagnosis does not support the test, documentation is missing, coverage rules are not met, or frequency limits are triggered. These are often order-level failures that happen before billing ever sees the claim.
Denials are expensive even when they are successfully appealed.
Premier’s 2023 claims survey reported that the average administrative cost to adjudicate a denied claim rose to $57.23 per claim. HFMA and industry sources also report that many denied claims are never reworked, often because the claim value is too low, the team is overloaded, or the appeal is not worth the staff time.
For labs, this matters more than it does for hospitals. Lab claims usually have lower individual reimbursement than surgical or imaging services. That means even recoverable denials can become quiet write-offs when the cost of rework is too high.
This concern is also reflected in the views of Ritesh Ramesh, CEO of MDaudit. This healthcare compliance analytics platform tracks billing, denial, and audit risk across large volumes of claims. As he stated in 2025, “Reactively fixing denials after they occur or addressing compliance findings after the fact is costly and unsustainable.”
The financial impact grows quickly at scale. The example below uses a hypothetical lab processing 2,000 claim lines per month, along with XiFin’s reported 19.3% denial rate and Premier’s estimated $57.23 administrative cost per denied claim, to show how these numbers can add up.
| What to calculate | Formula | Example |
|---|---|---|
| Denied claim lines | Monthly claim lines × denial rate | 2,000 × 19.3% = 386 |
| Monthly rework cost | Denied claim lines × $57.23 | 386 × $57.23 = $22,091 |
| Claims never reworked | Denied claim lines × 65% | 386 × 65% = 251 |
| Silent write-off risk | Claims never reworked × average reimbursement | 251 × your average reimbursement |
At higher claim volumes, the operational burden scales even further.
The exact impact will vary by test mix, payer mix, reimbursement rates, staffing model, and how many denied claims are actually reworked. But the pattern is clear: fixing preventable denials after the fact is expensive.
That is not only a billing department problem. It is often an order-quality problem, and the billing team is left to absorb the consequences.
The practical question is how labs can catch those risks earlier, before the test is performed and before the claim is submitted. This is where AI can make denial prevention more proactive.
AI helps labs avoid medical necessity denials by catching risk earlier in the workflow.
For lab owners, this can mean fewer unpaid tests, fewer write-offs, and less claim rework. For lab teams, it means fewer incomplete or risky orders reaching billing too late.
Ideally, AI checks happen before testing, when the lab can still request clarification, review ABN needs, or stop duplicate orders. But AI can also support post-test review before claim submission.
The goal is not to replace staff or providers. It is to help them spot medical necessity, documentation, payer rule, and frequency risks before they become denials.
AI can compare the ordered test with the diagnosis code submitted by the provider.
If the diagnosis is too broad, missing, or not clearly connected to the test, AI can flag the order before it moves forward.
This gives the lab a chance to request clarification or route the order for review before the test becomes unpaid work.
AI should not suggest diagnosis codes just to make a claim payable. The ordering provider remains responsible for choosing accurate codes based on the patient’s condition and medical record.
Medical necessity depends on payer rules, not only clinical logic.
AI can help compare orders against payer-specific requirements, Medicare rules, LCDs, NCDs, frequency limits, and the lab’s internal billing logic.
This helps labs catch problems before the claim is submitted, such as a test that needs stronger documentation, a more specific diagnosis, or an ABN review.
Billing and compliance teams should still review high-risk cases. AI helps them focus on the orders most likely to create denial risk.
Many denials begin with poor order quality.
AI can review requisitions and flag missing diagnosis codes, incomplete patient details, missing insurance information, unclear ordering provider data, or absent clinical notes.
This is useful when orders come from portals, EHR connections, paper forms, faxed requisitions, or manual entry.
For lab staff, it means fewer issues to chase later. For billing teams, it means fewer claims arrive with preventable errors already built in.
Some tests are denied because they are repeated too soon or ordered more often than the payer allows.
AI can compare new orders with available order history, result history, or patient context to identify duplicate or frequency-related risks.
That does not mean the test should always be stopped. There may be a valid clinical reason for repeating it.
But the risk should be reviewed before the lab spends time, supplies, and staff effort on a test that may not be paid.
A warning is only useful if the right person sees it.
AI can send alerts to intake staff, billing teams, compliance teams, ordering providers, or clinical teams based on the issue.
Missing patient details may go to intake. Unsupported diagnosis codes may go back to the ordering provider. ABN risks may go to the team responsible for Medicare workflows.
This helps labs avoid one of the biggest workflow problems: finding the issue too late or sending it to the wrong person.
AI can also help labs understand where medical necessity denials keep coming from.
It can analyze patterns across payers, ordering providers, test types, diagnosis codes, locations, and workflows.
For example, it may show that one payer denies a certain test more often, one provider group often sends incomplete requisitions, or one panel triggers frequent frequency-related denials.
These insights help labs improve order forms, strengthen documentation prompts, educate providers, and focus staff review on the highest-risk orders.
AI-assisted validation becomes more valuable when denial-related rework starts affecting revenue, staff time, and operations.
Labs may benefit most when they:
The main issue is not only denied claims. It is the cost of fixing preventable problems after testing, reporting, and billing work is already complete.
Not every denial-prevention tool is built for labs. Many systems were designed for hospitals or general RCM teams. Labs should ask more specific questions before choosing a solution.
Key questions include:
Solutions like Docus AI Compliance Agent can help labs bring these checks into one workflow, including order validation, medical necessity review, frequency checks, provider alerts, and documentation support before claims are submitted.
AI can improve workflows, but poor implementation can create new problems.
One common issue is alert overload. If too many low-risk orders are flagged, staff may start ignoring warnings. Provider pushback can also happen if clarification requests slow down ordering workflows.
Problems also appear when payer rules are configured too aggressively, causing clinically appropriate tests to be flagged unnecessarily.
The most effective workflows usually start with targeted validation rules focused on the highest-risk denials, not every possible issue. Labs also need human oversight, payer-specific tuning, and clear routing workflows so alerts reach the right people without slowing operations unnecessarily.
The goal is not to stop every risky order. It is to prioritize the orders most likely to create denial or audit risk while keeping workflows moving.
Most labs do not replace their LIS when adding AI validation tools. AI usually works as an additional review layer around existing workflows.
In practice, implementation often includes:
Some labs start with requisition workflows before expanding into deeper LIS or billing integration.
This version feels more implementation-focused and less repetitive.
Share via:
Talk to Docus AI Doctor, generate health reports, get them validated by Top Doctors from the US and Europe.
